EUCTR2014-004334-26-Outside-EU/EEA进行中（未招募）不适用
A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study
CB Japan Co. Ltd0 个研究点目标入组 398 人开始时间: 2015年2月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 398
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who participated in study N01221 [NCT00280696] and completed the evaluation period and transition period or patients who participated in study N01020 [NCT00160615]
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 18
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 380
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Female patients during pregnancy, delivery and lactation, or suspected of pregnancy
研究者
相似试验
尚未招募
4 期
An Observational study to evaluate the safety and effectiveness of Rejoint Max® in Indian Patients with Osteoarthritis of KneeCTRI/2020/03/023852Abbott Healthcare Pvt Ltd
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisEUCTR2019-004294-13-GBGalderma S.A.400
招募中
3 期
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.chronic skin inflammation10014982atopic dermatitisNL-OMON54779Galderma15
招募中
3 期
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo NodularisNL-OMON54290Galderma10
进行中（未招募）
1 期
ong-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersAtopic DermatitisEUCTR2019-001889-15-NLGalderma S.A.1,749